Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents

EuroIntervention

Volumn 6, Issue 1, 2010, Pages 117-125

  Van Beusekom, Heleen M M ^a   Sorop, Oana ^a   Van Den Heuvel, Mieke ^a   Onuma, Yoshinobu ^a   Duncker, Dirk J ^a   Danser, A H Jan ^a   Van Der Giessen, Willem J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Delayed healing; Drug eluting stents; Endothelium; Microcirculation; Neointima; Nitric oxide; Paclitaxel ; Sirolimus ; Stent thrombosis; Tacrolimus

Indexed keywords

CLOPIDOGREL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PACLITAXEL; RAPAMYCIN; TACROLIMUS; VON WILLEBRAND FACTOR; CARDIOVASCULAR AGENT; METAL; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; BIOAVAILABILITY; CELL FUNCTION; CONTROLLED STUDY; CORONARY STENT; DRUG ACTIVITY; DRUG ELUTING STENT; ENDOTHELIAL RESTORATION; ENDOTHELIUM CELL; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MICROVASCULATURE; MORPHOMETRICS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SWINE; VASOMOTOR REFLEX; ANGIOCARDIOGRAPHY; ANIMAL; CELL PROLIFERATION; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INSTRUMENTATION; METABOLISM; MICROCIRCULATION; PATHOLOGY; PATHOPHYSIOLOGY; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; METALS; MICROCIRCULATION; MICROSCOPY, ELECTRON, SCANNING; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PACLITAXEL; SIROLIMUS; STENTS; SWINE; TACROLIMUS; TIME FACTORS; VASODILATION; VASODILATOR AGENTS; VON WILLEBRAND FACTOR;

EID: 77954695664     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I1A18     Document Type: Article

References (48)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780. (Pubitemid 34586912)
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. (Pubitemid 37186209)
3. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545. (Pubitemid 36437930)
4. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521. (Pubitemid 39410418)
5. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092. (Pubitemid 40814135)
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-2441. (Pubitemid 46717966)
7. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270-278. (Pubitemid 40982311)
8. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342. (Pubitemid 352001347)
9. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46:231-236. (Pubitemid 40966848)
10. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166-170. (Pubitemid 43069032)
11. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, Lim SM, Jeon DS, Chung WS, Baek SH, Lee MY. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J. 2007;48:553-567.
12. Walker LN, Bowyer DE. Endothelial healing in the rabbit aorta and the effect of risk factors for atherosclerosis. Hypercholesterolemia. Arteriosclerosis 1984;4:479-488. (Pubitemid 14004794)
13. Prescott MF, Muller KR. Endothelial regeneration in hypertensive and genetically hypercholesterolemic rats. Arteriosclerosis 1983;3:206-214.
14. van Beusekom H, Sorop O, Weymaere M, Duncker D, van der Giessen W. The neointimal response to stents eluting tacrolimus from a degradable coating depends on the balance between polymer degradation and drug release. EuroIntervention. 2008;4:139-147.
15. Tanimoto S, van der Giessen WJ, van Beusekom HMM, Sorop O, Kukreja N, Fukaya T, Nishide T, Nakano R, Maeda H, Serruys PWS. MAHOROBA: Tacrolimus eluting coronary stent. EuroIntervention. 2007:149-153.
16. Commandeur S, van Beusekom HM, van der Giessen WJ. Polymers, drug release, and drug-eluting stents. J Interv Cardiol. 2006;19:500-506. (Pubitemid 44722241)
17. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80:S40-45.
18. St Peter SD, Moss AA, Mulligan DC. Effects of tacrolimus on ischemia-reperfusion injury. Liver Transpl. 2003;9:105-116. (Pubitemid 36204559)
19. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-2729. (Pubitemid 39665325)
20. Cowan PA, Heizer KE. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Nephrol Nurs J. 2000;27:623-625.
21. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-479. (Pubitemid 32678280)
22. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561-1565. (Pubitemid 10073801)
23. van Der Giessen WJ, Regar E, Harteveld MS, Coen VL, Bhagwandien R, Au A, Levendag PC, Ligthart J, Serruys PW, den Boer A, Verdouw PD, Boersma E, Hu T, van Beusekom HM. "Edge Effect" of (32)p radioactive stents is caused by the combination of chronic stent injury and radioactive dose falloff. Circulation. 2001;104:2236-2241.
24. van Beusekom HM, Whelan DM, Hofma SH, Krabbendam SC, van Hinsbergh VW, Verdouw PD, van der Giessen WJ. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol. 1998;32:1109-1117. (Pubitemid 28459607)
25. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, van Beusekom HM. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart. 2000;83:338-345. (Pubitemid 30313341)
26. Derkx P, Nigg AL, Bosman FT, Birkenhager-Frenkel DH, Houtsmuller AB, Pols HA, van Leeuwen JP. Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacrylate-embedded adult human bone in combination with histomorphometry. Bone. 1998;22:367-373. (Pubitemid 28177190)
27. Batenburg WW, Popp R, Fleming I, de Vries R, Garrelds IM, Saxena PR, Danser AH. Bradykinin-induced relaxation of coronary microarteries: Snitrosothiols as EDHF? Br J Pharmacol. 2004;142:125-135.
28. Batenburg WW, de Vries R, Saxena PR, Danser AH. L-S-nitrosothiols: endothelium-derived hyperpolarizing factors in porcine coronary arteries? J Hypertens. 2004;22:1927-1936.
29. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296-2301. (Pubitemid 38656868)
30. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977;41:19-26. (Pubitemid 8132079)
31. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910-916. (Pubitemid 47300915)
32. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108-2111.
33. Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am Heart J. 2006;152:1168-1174. (Pubitemid 44854799)
34. Yao ZH, Matsubara T, Inada T, Suzuki Y, Suzuki T. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: evaluation by optical coherence tomography. Chin Med J (Engl). 2008;121:503-507. (Pubitemid 351479628)
35. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL. Twentyeight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13:183-188. (Pubitemid 34747967)
36. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193. (Pubitemid 32830406)
37. Seifert PS, Huibregtse BA, Polovick J, Poff B. Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries. Cardiovasc Revasc Med. 2007;8:251-258. (Pubitemid 350161453)
38. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. Cardiovasc Res. 2007;76:361-372. (Pubitemid 350214456)
39. Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos. 1998;26:83-84. (Pubitemid 28071330)
40. Metcalfe S, Svvennsen R, Calne RY. FK506 and rapamycin: differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes. Transpl Int. 1992;5 Suppl 1:S514-515.
41. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant. 1997;16:484-492. (Pubitemid 27287777)
42. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
43. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373-1380. (Pubitemid 47449734)
44. Togni M, Raber L, Cocchia R, Wenaweser P, Cook S, Windecker S, Meier B, Hess OM. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol. 2007;120:212-220. (Pubitemid 47042255)
45. Kuga T, Egashira K, Mohri M, Tsutsui H, Harasawa Y, Urabe Y, Ando S, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation. 1995;92:183-189.
46. Cowan CL, McKenzie JE. Cholinergic regulation of resting coronary blood flow in domestic swine. Am J Physiol. 1990;259(1 Pt 2):H109-115.
47. Furusho N, Araki H, Sakaino N, Nishi K, Miyauchi Y. Effects of perivascular nerve stimulation on the flow rate in isolated epicardial coronary arteries of pigs. Eur J Pharmacol. 1988;154:79-84.
48. Hata H, Egashira K, Fukai T, Ohara Y, Kasuya H, Takahashi T, Takeshita A. The role of endothelium-derived nitric oxide in acetylcholine-induced coronary vasoconstriction in closed-chest pigs. Coron Artery Dis. 1993;4:891-898. (Pubitemid 23350196)